^
    14h
    EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. (PubMed, Nat Commun)
    We also uncover unexpected variability in the mutational landscape of successive biopsies, pointing to frequent co-existence of different clones and cautioning against stratifying patients based on single sampling. Our results clarify how oncogenic PRC2 mutations disrupt chromatin and transcription, and the therapeutic vulnerabilities this creates.
    Journal
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    EZH2 mutation • EZH2 Y641F • EZH2 Y641 • PRC2 mutation • EZH2 wild-type
    1d
    Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (clinicaltrials.gov)
    P1, N=100, Recruiting, Newave Pharmaceutical Inc | Trial completion date: Aug 2024 --> Oct 2025 | Trial primary completion date: Aug 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    LP-118
    2d
    Primary lymphoma of the female genital tract masquerading as gynecological malignancy. (PubMed, BMC Womens Health)
    PLFGT usually presents as gynecological symptoms and solid masses in pelvis. Surgery or biopsy was the way to obtain the pathologic diagnosis, and combination chemotherapy is the efficient method for PLFGT. Making an accurate preoperative diagnosis is of paramount importance to avoid radical gynecologic surgery.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    MUC16 elevation
    2d
    A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Marcela V. Maus, M.D.,Ph.D. | Completed --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2025 | Trial primary completion date: Oct 2022 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    Yescarta (axicabtagene ciloleucel) • Kineret (anakinra)
    3d
    MPCT-012L: Study of IMPT-314 in R/R Aggressive B-cell NHL (clinicaltrials.gov)
    P1/2, N=150, Recruiting, ImmPACT Bio | N=100 --> 150
    Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    IMPT-314
    3d
    17P.176: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas (clinicaltrials.gov)
    P2, N=30, Recruiting, Sidney Kimmel Cancer Center at Thomas Jefferson University | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    3d
    ATRIUM: A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (clinicaltrials.gov)
    P1, N=88, Recruiting, Antengene Discovery Limited | Trial primary completion date: Mar 2024 --> Jun 2024
    Trial primary completion date • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCF (FA complementation group F) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)
    |
    TP53 mutation • FANCF mutation
    |
    ATG-018
    4d
    MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases. (PubMed, Diagn Pathol)
    MNDA was highly expressed in MZL with a potential utility in differential diagnosis between MZL and RLH as well as FL, whereas its value in distinguishing MZL from MCL, CLL/SLL is limited. In addition, MNDA expression in DLBCL was more frequently seen in the non-GCB group and the BCL2/MYC double-expression group, and demonstrated a correlation with CD5, which deserves further investigation. The clinical relevance of MNDA and its correlation with the prognosis of these lymphomas also warrant to be fully elucidated.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD5 (CD5 Molecule)
    |
    BCL2 expression • MYC expression
    4d
    Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. (PubMed, Signal Transduct Target Ther)
    Grade 3 or higher treatment-related adverse events were observed in 63 (76.8%) cases, with neutropenia (22.0%), hyperglycemia (19.5%), and diarrhea (13.4%) being common. TQ-B3525 showed favorable efficacy and safety for R/R FL patients after ≥2 lines prior therapies.
    P2 data • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    TQ-B3525
    6d
    SYMPHONY-1: Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=612, Recruiting, Epizyme, Inc. | Trial completion date: Mar 2029 --> Apr 2032 | Trial primary completion date: Mar 2026 --> Sep 2029
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit)
    |
    EZH2 mutation
    |
    Rituxan (rituximab) • lenalidomide • Tazverik (tazemetostat)
    8d
    Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2/3, N=422, Recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Onureg (azacitidine oral) • Mabtas (rituximab biosimilar)
    8d
    SWOG S1608: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (clinicaltrials.gov)
    P2, N=95, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD)
    9d
    CO41942: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (clinicaltrials.gov)
    P1/2, N=187, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Nov 2027 --> Feb 2024
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 expression
    |
    lenalidomide • Actemra IV (tocilizumab) • Lunsumio (mosunetuzumab-axgb)
    10d
    Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
    Enrollment open • CAR T-Cell Therapy
    10d
    A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=105, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P2 trial
    |
    SHR-2554
    13d
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively. (PubMed, Leuk Lymphoma)
    The former is considered to be mediated by VDJ-recombination, while the latter by the class switch recombination process. There were no particular features in FL or CLL cases with IGH::5' BCL2 breakpoints compared with those with t(14;18)(q32;q21)/IGH::BCL2 involving the 3' breakpoint cluster regions.
    Journal
    |
    BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 fusion
    13d
    RaDD: A Trial of Radiotherapy and Durvalumab in DLBCL and FL (clinicaltrials.gov)
    P1, N=34, Completed, Austin Health | Active, not recruiting --> Completed
    Trial completion
    |
    CD20 positive
    |
    Imfinzi (durvalumab)
    14d
    Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (clinicaltrials.gov)
    P2, N=148, Active, not recruiting, Daiichi Sankyo | Trial completion date: Sep 2025 --> Apr 2028
    Trial completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD8 (cluster of differentiation 8)
    |
    ALK positive • ALK negative
    |
    Ezharmia (valemetostat)
    14d
    Patients with Classic Hodgkin Lymphoma and Follicular Lymphoma Compared to Single Malignancy Controls. (PubMed, Am J Surg Pathol)
    BCL2 translocations were detected in 4 of the 7 cases with FL, but in positive cases, the rearrangement was also present in the CHL component, indicating a clonal relationship between FL and CHL. Patients with FL and CHL treated for CHL had an initial outcome more similar to FL than to CHL controls.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 translocation
    14d
    Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Washington | Trial completion date: Aug 2028 --> Aug 2029 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    Opdivo (nivolumab)
    15d
    GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
    P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • ADI-001
    15d
    Radiation Post-CAR T in Refractory Lymphoma (clinicaltrials.gov)
    P=N/A, N=3, Terminated, Massachusetts General Hospital | N=20 --> 3 | Trial completion date: May 2024 --> Jul 2023 | Not yet recruiting --> Terminated; Futility
    Enrollment change • Trial completion date • Trial termination • CAR T-Cell Therapy
    17d
    Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Beth Christian | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • lenalidomide • Gazyva (obinutuzumab)
    18d
    ZUMA-24: Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Kite, A Gilead Company | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • fludarabine IV
    21d
    ZUMA-22: Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov)
    P3, N=230, Recruiting, Kite, A Gilead Company | Trial completion date: Jan 2031 --> Oct 2030 | Trial primary completion date: Jan 2031 --> Oct 2030
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Yescarta (axicabtagene ciloleucel) • bendamustine • fludarabine IV
    21d
    Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas (clinicaltrials.gov)
    P2, N=43, Recruiting, H. Lee Moffitt Cancer Center and Research Institute
    New P2 trial
    |
    Brukinsa (zanubrutinib) • Rituxan Hycela (rituximab/hyaluronidase)
    21d
    Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=396, Recruiting, SWOG Cancer Research Network | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date • CAR T-Cell Therapy
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Breyanzi (lisocabtagene maraleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)
    21d
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    P-CD19CD20-ALLO1 • rimiducid (AP1903)
    21d
    BAH241: Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (clinicaltrials.gov)
    P1/2, N=75, Not yet recruiting, Essen Biotech | Initiation date: Feb 2024 --> Nov 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide
    21d
    PORTAL: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=99, Not yet recruiting, University College, London | Trial completion date: Jan 2028 --> Jul 2028 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2028 --> Jan 2027
    Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    21d
    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD4 (CD4 Molecule)
    |
    bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)
    21d
    Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    Imbruvica (ibrutinib)
    21d
    BGB-16673-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=466, Recruiting, BeiGene | N=291 --> 466
    Enrollment change
    |
    BGB-16673
    22d
    Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (clinicaltrials.gov)
    P2, N=27, Recruiting, Patrick C. Johnson, MD | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Mar 2029 | Trial primary completion date: Sep 2024 --> Mar 2025
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • Calquence (acalabrutinib) • Breyanzi (lisocabtagene maraleucel) • fludarabine IV
    22d
    Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (clinicaltrials.gov)
    P2, N=54, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • thiotepa
    22d
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (clinicaltrials.gov)
    P1, N=120, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    23d
    Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (clinicaltrials.gov)
    P2, N=60, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=24 --> 60
    Enrollment closed • Enrollment change
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Calquence (acalabrutinib)
    23d
    ASTX660-03: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (clinicaltrials.gov)
    P1/2, N=132, Active, not recruiting, Astex Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Inqovi (decitabine/cedazuridine) • tolinapant (ASTX660)
    23d
    Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Roswell Park Cancer Institute
    New P1 trial • CAR T-Cell Therapy
    |
    cyclophosphamide • fludarabine IV
    24d
    AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas (clinicaltrials.gov)
    P1, N=120, Not yet recruiting, Stanford University
    New P1 trial • CAR T-Cell Therapy
    |
    CD22 (CD22 Molecule)
    26d
    Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial. (PubMed, BMC Cancer)
    Whilst there are many promising novel drugs in early clinical development for rrFL, understanding the relative efficacy and safety of these agents, and their place in modern treatment pathways, is limited by a lack of randomised trials and dearth of published outcomes for standard regimens to act as historic controls. Therefore, the aim of REFRACT is to provide an efficient platform to evaluate novel agents against standard therapies for rrFL. The adaptive Bayesian power prior methodology design will minimise patient numbers and accelerate trial delivery.
    Clinical protocol • P2 data • Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    26d
    Studies on clinicopathological features of duodenal-type follicular lymphoma of 18 patients (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Median follow-up was 12 (2-34) months. This study shows that D-FL is an indolent lymphoma, which tends to occur in the duodenum and has a good prognosis.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    BCL2 expression • CD20 expression • BCL2 rearrangement